Please assess the completion status of the following clinical trial:

Trial Title: Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (\> 18 years of age) patients with documented HCC tumor mass \>3cm, who are scheduled to undergo TACE with additional selective internal radiation therapy (SIRT)~* The appropriate criteria for inclusion for this patient population are:~* Biopsy or radiological diagnosis of HCC (defined as Organ Procurement and Transplantation Network (OPTN\*) Category 5 lesion either on CT or MRI)~* Scheduled for TACE (using doxorubicin-eluting beads) + SBRT~* Willingness to undergo PET/CT~* Able to lie on the imaging table for up to 1 hour.~* Able to provide signed informed consent.~* Women with childbearing potential must have a negative urine Beta-Human Chorionic Gonadotropin (β-hCG) test day of procedure~Exclusion Criteria:~* Estimated life expectancy \<12 months or serious medical co-morbidities that would preclude definitive local therapy~* Unable to lie on the imaging table~* Age less than 18 years.~* Pregnancy or lactation~* Inability or unwillingness to provide informed consent.~* Weight \>500 lbs (the weight limit of the tomograph gantry table)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMISO PET imaging post TACE and Stereotactic body radiation therapy (SBRT) (Type: EXPERIMENTAL): FMISO imaging at baseline, post-TACE and post-SBRT

Based on this trial design, predict the completion outcome and termination type (if applicable).